TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years October 26, 2012
TCL Archive FDA Grants Approvals to Lynparza, Blincyto, Xgeva, Gardasil 9 and Cyramza December 26, 2014
TCL Archive Academic Oncologists Reluctant To Give ESAs In Adjuvant Breast Cancer Setting. December 7, 2007